Additionally, it was aimed at comparing ovarian reserves and AMH levels with parameters such as height, weight, body mass index (BMI), history of drug use, amyloidosis, disease severity, and MEFV gene mutations in patients with FMF. The gene discussed is AMH; the disease is amyloidosis.